Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585121 | 0.98 | DPP7 (0.41) | DPP7SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5672147 | 0.87 | — | — | |
| SCHEMBL1615519 | 0.87 | OPRM1 (0.31) | DPP7SLC6A3 | |
| SCHEMBL7771636 | 0.86 | HRH3 (0.42) | DPP7SLC6A3HRH3MAPTMAPK1 | |
| SCHEMBL5839699 | 0.85 | OPRM1 (0.43) | DPP7HRH3MAPTMAPK1NPSR1 | |
| SCHEMBL8390873 | 0.85 | OPRM1 (0.43) | DPP7HRH3MAPTMAPK1NPSR1 | |
| SCHEMBL2914564 | 0.84 | HRH3 (0.40) | DPP7SLC6A3SLC6A2HRH3MAPT | |
| SCHEMBL486442 | 0.80 | DPP7 (0.47) | DPP7 | |
| SCHEMBL28047132 | 0.78 | DPP7 (0.45) | DPP7 | |
| SCHEMBL8557598 | 0.77 | KMT2A (0.37) | SLC6A3SLC6A2SLC6A4MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113087654-B | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-113087654-A | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2021-07-09 | — | — | CN | claimed |
| CN-113087654-B | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-113087654-B | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-113087654-B | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-113087654-A | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-113087654-A | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-113087654-A | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| WO-2012038905-A1 | THIENOPYRIDINE NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012038904-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-29 | — | — | WO | disclosed |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20100016343-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016360-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| CN-101495465-A | 2-phenyl-5-amino-1,3,4-oxadiazoles and their use as nicotinic acetylcholine receptor ligands | GLAXO GROUP LTD (GB) | 2009-07-29 | — | — | CN | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| EP-2021331-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| US-5153327-A | 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E. R. SQUIBB & SONS, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5100889-A | Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| US-4273850-A | 2,5-DIALKOXY-4-ARYLMERCAPTOBENZENE DIAZONIUM SALTS AND A HYDROXYNAPHTHALENE DISULFONAMIDE COUPLER | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | DPP7 862/4885SLC6A3 456/4885SLC6A2 341/4885 |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | NAMPT, NNT, NQO1 | DPP7 1947/4885SLC6A3 1701/4885SLC6A2 605/4885 |
| US-20100016343-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | DPP7 479/4885SLC6A3 443/4885SLC6A2 372/4885 |
| US-20100016360-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | DPP7 479/4885SLC6A3 443/4885SLC6A2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.